Undervalued Large-Cap Healthcare Stocks on NAS June 2025

June 17, 2025

Healthcare Sector

The healthcare sector includes companies in biotechnology, pharmaceuticals, hospitals, home and long-term care. It also includes related medical equipment manufacturers and suppliers.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Healthcare stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
SRPT Sarepta Therapeutics 37.60 76.50 103.46 5730379 3661 0.00 0.0
ACHC Acadia Healthcare Co 22.61 44.00 94.60 2381117 2081 0.00 11.1
REGN Regeneron Pharmaceuticals 490.28 828.09 68.90 1478973 54519 0.36 12.5
BMRN Biomarin Pharmaceutical 58.07 92.00 58.43 2180190 11409 0.00 21.5
IBRX ImmunityBio 2.64 3.90 47.76 10937387 2252 0.00 0.0
HRMY Harmony Biosciences Hldgs 34.46 50.80 47.43 752079 2017 0.00 13.2
LNTH Lantheus Holdings 75.53 110.27 46.00 1497578 5397 0.00 21.5
QDEL QuidelOrtho 30.68 44.50 45.05 1906079 2071 0.00 0.0
IMVT Immunovant 14.85 21.27 43.26 1153875 2251 0.00 0.0
JAZZ Jazz Pharmaceuticals 107.98 152.63 41.35 1347465 6585 0.00 14.7
All data provided as at market close May 29, 2025.

Company Details

Sarepta Therapeutics

SRPT:NAS

Close Price

37.60

Our Valuation

76.50

% Difference

103.46

Market Cap ($M)

3661

P/E Ratio

0.0

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates.

Access the stockcalc valuation


Acadia Healthcare Co

ACHC:NAS

Close Price

22.61

Our Valuation

44.00

% Difference

94.60

Market Cap ($M)

2081

P/E Ratio

11.1

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.

Access the stockcalc valuation


Regeneron Pharmaceuticals

REGN:NAS

Close Price

490.28

Our Valuation

828.09

% Difference

68.90

Market Cap ($M)

54519

P/E Ratio

12.5

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis.

Access the stockcalc valuation


Biomarin Pharmaceutical

BMRN:NAS

Close Price

58.07

Our Valuation

92.00

% Difference

58.43

Market Cap ($M)

11409

P/E Ratio

21.5

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

ImmunityBio

IBRX:NAS

Close Price

2.64

Our Valuation

3.90

% Difference

47.76

Market Cap ($M)

2252

P/E Ratio

0.0

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies.

Access the stockcalc valuation


Harmony Biosciences Hldgs

HRMY:NAS

Close Price

34.46

Our Valuation

50.80

% Difference

47.43

Market Cap ($M)

2017

P/E Ratio

13.2

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy.

Access the stockcalc valuation


Lantheus Holdings

LNTH:NAS

Close Price

75.53

Our Valuation

110.27

% Difference

46.00

Market Cap ($M)

5397

P/E Ratio

21.5

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer.

Access the stockcalc valuation


QuidelOrtho

QDEL:NAS

Close Price

30.68

Our Valuation

44.50

% Difference

45.05

Market Cap ($M)

2071

P/E Ratio

0.0

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Access the stockcalc valuation


Immunovant

IMVT:NAS

Close Price

14.85

Our Valuation

21.27

% Difference

43.26

Market Cap ($M)

2251

P/E Ratio

0.0

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Access the stockcalc valuation


Jazz Pharmaceuticals

JAZZ:NAS

Close Price

107.98

Our Valuation

152.63

% Difference

41.35

Market Cap ($M)

6585

P/E Ratio

14.7

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Sarepta Therapeutics and Acadia Healthcare are the most undervalued Large-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-june-2025
Sarepta Therapeutics $SRPT and Acadia Healthcare $ACHC are the most undervalued Healthcare stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-june-2025
Sarepta Therapeutics and Acadia Healthcare are the most undervalued Large-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-june-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.